Richard L. Kravitz, MD, MSPH and Jodi Halpern, MD, PhD
Patients have a responsibility to discerningly present the drug information they receive from direct-to-consumer advertising and to be active partners with their physician in making health care decisions.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Amy B. Cadwallader, PhD, Kavitha Nallathambi, MPH, MBA, and Carly Ching, PhD
Poor-quality antimicrobial medicines continue to proliferate across supply chains, threatening patients’ health and safety, especially in low- and middle-income regions.
AMA J Ethics. 2024;26(6):E472-478. doi:
10.1001/amajethics.2024.472.
The concept stewardship borrows from collective action problems that cannot be solved by individuals only, just like those discussed in environmental ethics.
AMA J Ethics. 2024;26(6):E479-485. doi:
10.1001/amajethics.2024.479.
Amy Fairchild, PhD, MPH, Ronald Bayer, PhD, and James Colgrove, PhD, MPH
A brief history of public opposition to disease surveillance in the U.S., despite the documented success of this tool in recognizing and managing threats to public health.
Raphael P. Viscidi, MD and Keerti V. Shah, MD, DrPH
The arguments for mandatory vaccination with human papillomavirus vaccine differs from the justification for mandatory use of vaccines that protect against more easily transmitted diseases.
In a study of New York physicians' compliance with reporting of communicable diseases, surveyed physicians responded better to legal warnings than to requests that explained public health benefits.